These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1014 related articles for article (PubMed ID: 24674926)
1. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Jamal JA; Udy AA; Lipman J; Roberts JA Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926 [TBL] [Abstract][Full Text] [Related]
2. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R; Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. Adnan S; Li JX; Wallis SC; Rudd M; Jarrett P; Paterson DL; Lipman J; Udy AA; Roberts JA Int J Antimicrob Agents; 2013 Jul; 42(1):90-3. PubMed ID: 23590897 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259 [TBL] [Abstract][Full Text] [Related]
6. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872 [TBL] [Abstract][Full Text] [Related]
8. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Kielstein JT; Czock D; Schöpke T; Hafer C; Bode-Böger SM; Kuse E; Keller F; Fliser D Crit Care Med; 2006 Jan; 34(1):51-6. PubMed ID: 16374156 [TBL] [Abstract][Full Text] [Related]
10. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of meropenem in critically ill patients with severe infections. Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279 [TBL] [Abstract][Full Text] [Related]
12. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706 [TBL] [Abstract][Full Text] [Related]
13. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA; Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084 [TBL] [Abstract][Full Text] [Related]
14. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Udy AA; Covajes C; Taccone FS; Jacobs F; Vincent JL; Lipman J; Roberts JA Int J Antimicrob Agents; 2013 Jun; 41(6):564-8. PubMed ID: 23473944 [TBL] [Abstract][Full Text] [Related]
15. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853 [TBL] [Abstract][Full Text] [Related]
17. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA; J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783 [TBL] [Abstract][Full Text] [Related]
18. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163 [TBL] [Abstract][Full Text] [Related]